vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $20.4M, roughly 1.5× Sight Sciences, Inc.). Sight Sciences, Inc. runs the higher net margin — -20.4% vs -438.1%, a 417.7% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 6.9%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 2.9%).
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
DOMH vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $20.4M |
| Net Profit | $-131.8M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | -8.9% | -18.0% |
| Net Margin | -438.1% | -20.4% |
| Revenue YoY | 220.4% | 6.9% |
| Net Profit YoY | -12426.2% | 64.9% |
| EPS (diluted) | $-6.94 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $20.4M | ||
| Q3 25 | $50.8M | $19.9M | ||
| Q2 25 | $34.1M | $19.6M | ||
| Q1 25 | $8.1M | $17.5M | ||
| Q4 24 | $9.4M | $19.1M | ||
| Q3 24 | $4.0M | $20.2M | ||
| Q2 24 | $6.2M | $21.4M | ||
| Q1 24 | $1.4M | $19.3M |
| Q4 25 | $-131.8M | $-4.2M | ||
| Q3 25 | $125.2M | $-8.2M | ||
| Q2 25 | $16.6M | $-11.9M | ||
| Q1 25 | $-32.5M | $-14.2M | ||
| Q4 24 | $1.1M | $-11.8M | ||
| Q3 24 | $-4.2M | $-11.1M | ||
| Q2 24 | $-6.1M | $-12.3M | ||
| Q1 24 | $-5.4M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | -8.9% | -18.0% | ||
| Q3 25 | -3.1% | -39.7% | ||
| Q2 25 | -57.0% | -59.6% | ||
| Q1 25 | -394.6% | -79.2% | ||
| Q4 24 | 0.4% | -62.5% | ||
| Q3 24 | -79.1% | -55.7% | ||
| Q2 24 | -44.3% | -59.2% | ||
| Q1 24 | -205.2% | -76.4% |
| Q4 25 | -438.1% | -20.4% | ||
| Q3 25 | 246.4% | -41.0% | ||
| Q2 25 | 48.7% | -61.0% | ||
| Q1 25 | -400.5% | -80.8% | ||
| Q4 24 | 11.4% | -62.1% | ||
| Q3 24 | -104.2% | -54.9% | ||
| Q2 24 | -99.1% | -57.7% | ||
| Q1 24 | -398.0% | -84.4% |
| Q4 25 | $-6.94 | $-0.07 | ||
| Q3 25 | $7.27 | $-0.16 | ||
| Q2 25 | $1.12 | $-0.23 | ||
| Q1 25 | $-3.02 | $-0.28 | ||
| Q4 24 | $0.21 | $-0.23 | ||
| Q3 24 | $-0.67 | $-0.22 | ||
| Q2 24 | $-1.01 | $-0.25 | ||
| Q1 24 | $-0.91 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $69.4M | $63.9M |
| Total Assets | $112.9M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $92.0M | ||
| Q3 25 | $176.2M | $92.4M | ||
| Q2 25 | $28.2M | $101.5M | ||
| Q1 25 | $18.9M | $108.8M | ||
| Q4 24 | $8.2M | $120.4M | ||
| Q3 24 | $7.2M | $118.6M | ||
| Q2 24 | $12.1M | $118.2M | ||
| Q1 24 | $7.1M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $69.4M | $63.9M | ||
| Q3 25 | $210.2M | $64.3M | ||
| Q2 25 | $88.6M | $70.0M | ||
| Q1 25 | $42.4M | $77.6M | ||
| Q4 24 | $39.9M | $87.5M | ||
| Q3 24 | $38.3M | $95.0M | ||
| Q2 24 | $42.4M | $101.6M | ||
| Q1 24 | $47.7M | $109.2M |
| Q4 25 | $112.9M | $115.3M | ||
| Q3 25 | $223.4M | $116.3M | ||
| Q2 25 | $109.3M | $122.0M | ||
| Q1 25 | $52.3M | $129.7M | ||
| Q4 24 | $47.1M | $142.8M | ||
| Q3 24 | $43.4M | $143.6M | ||
| Q2 24 | $49.1M | $149.7M | ||
| Q1 24 | $52.2M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-1.8M | ||
| Q3 25 | $-4.9M | $-8.7M | ||
| Q2 25 | $-353.0K | $-7.5M | ||
| Q1 25 | $1.2M | $-11.6M | ||
| Q4 24 | $-16.7M | $-3.5M | ||
| Q3 24 | $-4.7M | $362.0K | ||
| Q2 24 | $1.4M | $-9.5M | ||
| Q1 24 | $-8.6M | $-9.8M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
